Market research
INDSWFTLTD.NSE Ind-Swift Limited
NSE INR Not available
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 851M
- P/E ratio
- 0.3
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- -0.77
Profile
Company facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Not available
- Industry
- Not available
- ISIN
- INE788B01028
- Market cap
- 851M
- P/E ratio
- 0.3
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- -0.77
About
About Ind-Swift Limited
Ind-Swift Limited develops pharmaceutical formulations, finished goods dosages, active pharmaceutical ingredients, and herbal products in India. The company offers medicines for various therapeutic segments, such as ENT, dentistry, anti-infective, cardio-diabetic, and orthopedic therapies under the Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin, and Stemin Forte names. It also offers medicines for various therapeutic comprising gynaecology, pediatrics, dermatology, and other generic medicines under the Anin, Suprox, Cozy, Distone, and Oliade name. In addition, the company provides antibiotic, anti-cold, nutraceuticals, anti-diarrhoeal, anti-malarial, anti-depressants, cardiology, diabetology, anti-depressant, anti-allergic, anti- infective, neurology, and oncology. Ind-Swift Limited provides Ayurvedic products, as well as contract research and manufacturing services. The company exports its products, as well as licenses its products to Europe, Australia, Canada, South Africa, and Russia. Swift Limited was founded in 1983 and is based in Chandigarh, India. As of August 8, 2025, Ind-Swift Limited operates as a subsidiary of Ind-Swift Laboratories Limited.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the INDSWFTLTD.NSE discussion.
5 years, 4 months ago
Ind-Swift Limited is currently in a long term uptrend where the price is trading 12.2% above its 200 day moving average.
From a valuation standpoint, the stock is 97.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.1.
Ind-Swift Limited's total revenue rose by 9.4% to $1B since the same quarter in the previous year.
Its net income has increased by 89.9% to $-12M since the same quarter in the previous year.
Finally, its free cash flow grew by 308.2% to $295M since the same quarter in the previous year.
Based on the above factors, Ind-Swift Limited gets an overall score of 5/5.